Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
- Michael Schiff1,
- Michael E Weinblatt2,
- Robert Valente3,
- Désirée van der Heijde4,
- Gustavo Citera5,
- Ayanbola Elegbe6,
- Michael Maldonado6,
- Roy Fleischmann7
- 1Department of Rheumatology, University of Colorado, Denver, Colorado, USA
- 2Department of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA
- 3Department of Rheumatology, Arthritis Center of Nebraska, Lincoln, Nebraska, USA
- 4Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
- 5Department of Rheumatology, Instituto de Rehabilitación Psicofísica de Buenos Aires, Buenos Aires, Argentina
- 6Bristol-Myers Squibb, Princeton, New Jersey, USA
- 7Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
- Correspondence to Dr Michael Schiff, University of Colorado, School of Medicine, 5400 South Monaco Street, Greenwood Village, CO 80111, USA;
- Received 26 April 2013
- Revised 29 July 2013
- Accepted 29 July 2013
- Published Online First 20 August 2013
Objectives To compare over 2 years the safety, efficacy and radiographic outcomes of subcutaneous abatacept versus adalimumab, in combination with methotrexate (MTX), in patients with rheumatoid arthritis (RA).
Methods AMPLE is a phase IIIb, 2-year, randomised, investigator-blinded study with a 1-year primary endpoint. Biologic-naive patients with active RA and an inadequate response to MTX were randomised to 125 mg abatacept weekly or 40 mg adalimumab bi-weekly, both with a stable dose of MTX.
Results Of 646 patients randomised, 79.2% abatacept and 74.7% adalimumab patients completed year 2. At year 2, efficacy outcomes, including radiographic, remained comparable between groups and with year 1 results. The American College Rheumatology 20, 50 and 70 responses at year 2 were 59.7%, 44.7% and 31.1% for abatacept and 60.1%, 46.6% and 29.3% for adalimumab. There were similar rates of adverse events (AEs) and serious adverse events (SAEs). More serious infections occurred with adalimumab (3.8% vs 5.8%) including two cases of tuberculosis with adalimumab. There were fewer discontinuations due to AEs (3.8% vs 9.5%), SAEs (1.6% vs 4.9%) and serious infections (0/12 vs 9/19 patients) in the abatacept group. Injection site reactions (ISRs) occurred less frequently with abatacept (4.1% vs 10.4%).
Conclusions Through 2 years of blinded treatment in this first head-to-head study between biologic disease-modifying antirheumatic drugs in RA patients with an inadequate response to MTX, subcutaneous abatacept and adalimumab were similarly efficacious based on clinical, functional and radiographic outcomes. Overall, AE frequency was similar in both groups but there were less discontinuations due to AEs, SAEs, serious infections and fewer local ISRs with abatacept.
ClinicalTrials.gov Identifier NCT00929864.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/